Pfizer

Bayer Buys Teva Pharmaceutical to Expand Animal Health Franchise; Abbott Markets New Lung Cancer Test in EU - Health Minute for November 1, 2012

Press Release

Bayer will buy Teva Pharmaceutical, a U.S.-animal health business for $145 million. The acquisition reinforces the food animal franchise of Bayer Healthcare by providing a range of anti-infective solutions for livestock. It will also expand the company’s portfolio with dermatological, pet wellness, and nutraceutical products.

The Next Big Thing in Corporate Citizenship

Summary: 

International Employee Volunteering is about to become the next hot topic in CSR. Don't be confused, however; international and global volunteering are 2 entirely different things. Here are the differences - plus, who's ahead of the game and why it's important. 

READ THE BLOG HERE

Blog

International Employee Volunteering is about to become the next hot topic in CSR. Don't be confused, however; international and global volunteering are 2 entirely different things. Here are the differences - plus, who's ahead of the game and why it's important. 

READ THE BLOG HERE

NextBillion on How GE is Advancing Healthcare in Bottom of the Pyramid Markets

Summary: 

NextBillion, a blog that brings together business leaders, entrepreneurs, NGOs, policy makers and academics to explore the connection between development and enterprise, discusses how corporations are reaching Bottom of the Pyramid (BoP) markets with healthcare innovations.

This is part one of two in a set of articles on reaching BoP markets with healthcare innovations, and it addresses the perspective of several multinational corporations (including GE).

Blog

NextBillion, a blog that brings together business leaders, entrepreneurs, NGOs, policy makers and academics to explore the connection between development and enterprise, discusses how corporations are reaching Bottom of the Pyramid (BoP) markets with healthcare innovations.

This is part one of two in a set of articles on reaching BoP markets with healthcare innovations, and it addresses the perspective of several multinational corporations (including GE).

Last Chance to Register: The Business Case for Creating a Standalone Chief Compliance Officer

Summary: 

Featured Presenters:

  • Alan Yuspeh, Chief Ethics and Compliance Officer at HCA

  • Bill Lytton, Senior Counsel at Dechert LLP, former General Counsel, International Paper Company and Tyco International

  • Erica Salmon Byrne, Assistant General Counsel and Director, Advisory Services at Corpedia

Date: Tuesday, October 26, 2010
Time: 11:00 am PT / 2:00 pm ET
Price: $115, Complimentary for Ethisphere Council and BELA members.
 

 

Press Release

Featured Presenters:

  • Alan Yuspeh, Chief Ethics and Compliance Officer at HCA

  • Bill Lytton, Senior Counsel at Dechert LLP, former General Counsel, International Paper Company and Tyco International

  • Erica Salmon Byrne, Assistant General Counsel and Director, Advisory Services at Corpedia

Date: Tuesday, October 26, 2010
Time: 11:00 am PT / 2:00 pm ET
Price: $115, Complimentary for Ethisphere Council and BELA members.
 

 

Pages

Subscribe to Pfizer